News & Events
Upcoming Events
Tue, 5/24/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 5/26/2022 - 8:00 PM CT
For caregivers, family & friends - You don’t need to take on… more
Fri, 5/27/2022 - 6:30 PM
For patients/survivors - General meetup moderated by survivors
After… more
Tue, 5/31/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
May 19, 2022
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
May 19, 2022
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
May 19, 2022
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
May 19, 2022
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
May 18, 2022
Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements
May 18, 2022
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
May 18, 2022
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
May 17, 2022
Discovering a New Approach to Treat Metastatic NSCLC
May 17, 2022
Discovering a New Approach to Treat Metastatic NSCLC
Lung cancer continues to be the number-one cause of cancer deaths in the United States. In the past decade, we have seen great improvements in the treatment of metastatic lung cancer with targeted therapies and immunotherapy.
“When targeted therapies aren’t an option, the current standard of care for patients is immunotherapy alone or in combination with chemotherapy. But many patients don’t respond to these treatments the way we’d like them to,” said Sean Pitroda, MD, assistant professor of…
May 17, 2022
An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
May 17, 2022
An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
May 9, 2022
Survival Varies Little by Surgery Type in NSCLC With Micro Lesions
May 9, 2022
Segmentectomy “Should Be Standard” for Early-Stage Non-Small Cell Lung Cancer
May 9, 2022
A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients
May 9, 2022
A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients
May 2, 2022